Literature DB >> 17132722

Immunostimulatory RNA oligonucleotides trigger an antigen-specific cytotoxic T-cell and IgG2a response.

Carole Bourquin1, Laura Schmidt, Veit Hornung, Cornelia Wurzenberger, David Anz, Nadja Sandholzer, Susanne Schreiber, Andreas Voelkl, Gunther Hartmann, Stefan Endres.   

Abstract

Single-stranded RNA oligonucleotides containing an immunostimulatory motif (immunostimulatory RNA [isRNA]) are potent inducers of interferon-alpha via the Toll-like receptor 7. We investigated the effect of isRNA on the development of an immune response. We show that isRNA activates dendritic cells and induces production of Th1-type cytokines both in vitro and in vivo. Cytokine production led to bystander activation of T and B cells. We further demonstrate that isRNA triggers the generation of antigen-specific cytotoxic T cells and of an IgG2a-biased antibody response to antigen in a sequence-dependent manner. In summary, we provide evidence for the first time that isRNA oligonucleotides can simultaneously activate the innate and adaptive arms of the immune system.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17132722     DOI: 10.1182/blood-2006-07-033258

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

1.  Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides.

Authors:  Klaus Zwiorek; Carole Bourquin; Julia Battiany; Gerhard Winter; Stefan Endres; Gunther Hartmann; Conrad Coester
Journal:  Pharm Res       Date:  2007-10-03       Impact factor: 4.200

2.  JAK kinases are required for the bacterial RNA and poly I:C induced tyrosine phosphorylation of PKR.

Authors:  Farag Bleiblo; Paul Michael; Danielle Brabant; Chilakamarti V Ramana; Tc Tai; Mazen Saleh; Joseph E Parrillo; Anand Kumar; Aseem Kumar
Journal:  Int J Clin Exp Med       Date:  2012-11-18

3.  Bacterial RNA induces myocyte cellular dysfunction through the activation of PKR.

Authors:  Farag Bleiblo; Paul Michael; Danielle Brabant; Chilakamarti V Ramana; Tc Tai; Mazen Saleh; Joseph E Parrillo; Anand Kumar; Aseem Kumar
Journal:  J Thorac Dis       Date:  2012-04-01       Impact factor: 2.895

Review 4.  mRNA-based therapeutics--developing a new class of drugs.

Authors:  Ugur Sahin; Katalin Karikó; Özlem Türeci
Journal:  Nat Rev Drug Discov       Date:  2014-09-19       Impact factor: 84.694

Review 5.  Tuning the size, shape and structure of RNA nanoparticles for favorable cancer targeting and immunostimulation.

Authors:  Sijin Guo; Congcong Xu; Hongran Yin; Jordan Hill; Fengmei Pi; Peixuan Guo
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-08-27

6.  The role of immunostimulatory nucleic acids in septic shock.

Authors:  Farag Bleiblo; Paul Michael; Danielle Brabant; Chilakamarti V Ramana; Tc Tai; Mazen Saleh; Joseph E Parrillo; Anand Kumar; Aseem Kumar
Journal:  Int J Clin Exp Med       Date:  2012-01-15

7.  Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8.

Authors:  Tao Lan; Ekambar R Kandimalla; Dong Yu; Lakshmi Bhagat; Yukui Li; Daqing Wang; Fugang Zhu; Jimmy X Tang; Mallikarjuna R Putta; YanPing Cong; Anthony F Trombino; Tim Sullivan; Sudhir Agrawal
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-14       Impact factor: 11.205

8.  MyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded Toll-like receptor ligands.

Authors:  Angela Meier; Galit Alter; Nicole Frahm; Harlyn Sidhu; Bin Li; Aranya Bagchi; Nickolas Teigen; Hendrik Streeck; Hans-Juergen Stellbrink; Judith Hellman; Jan van Lunzen; Marcus Altfeld
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

9.  Drug delivery-mediated control of RNA immunostimulation.

Authors:  David N Nguyen; Steve C-Y Chen; James Lu; Michael Goldberg; Phillip Kim; Andrew Sprague; Tatiana Novobrantseva; Jennifer Sherman; Svetlana Shulga-Morskaya; Antonin de Fougerolles; Jianzhu Chen; Robert Langer; Daniel G Anderson
Journal:  Mol Ther       Date:  2009-07-07       Impact factor: 11.454

Review 10.  Non-Immunotherapy Application of LNP-mRNA: Maximizing Efficacy and Safety.

Authors:  Irena Vlatkovic
Journal:  Biomedicines       Date:  2021-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.